Go Pro

Harmony Biosciences (HRMY) 10K Form and Latest SEC Filings 2026

Harmony Biosciences logo
$39.15 +0.74 (+1.93%)
As of 12:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Harmony Biosciences SEC Filings & Recent Activity

Harmony Biosciences (NASDAQ:HRMY) has submitted 285+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Harmony Biosciences's financial statements. The most recent filing was a Form 144 submitted on August 7, 2026.

Form 4
Harmony Biosciences Holdings, Inc. Reports Ownership Change on May. 18, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Harmony Biosciences Files Current Report on Aug. 4, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Harmony Biosciences Files Quarterly Report on Aug. 4, 2026

The 10-Q contains Harmony Biosciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Harmony Biosciences SEC Filing History

Browse Harmony Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/07/2026 3:48 PM
Harmony Biosciences (1802665) Subject
Valor IV Pharma Holdings, LLC (1821186) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/04/2026 7:16 AM
Harmony Biosciences (1802665) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/04/2026 7:05 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2026 10:23 AM
Harmony Biosciences (1802665) Subject
VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by
Form SCHEDULE 13G
07/22/2026 3:04 PM
Harmony Biosciences (1802665) Issuer
Mollichella Stephen M. (2146210) Reporting
Form 3
Initial statement of beneficial ownership of securities  
07/16/2026 7:35 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/02/2026 3:06 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/30/2026 3:04 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 3:17 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2026 3:18 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2026 3:28 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 8:50 PM
Germano Geno J (1424383) Reporting
Harmony Biosciences (1802665) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/18/2026 8:51 PM
Germano Geno J (1424383) Reporting
Harmony Biosciences (1802665) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:15 PM
Harmony Biosciences (1802665) Issuer
Sender Gary (1659085) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:17 PM
Harmony Biosciences (1802665) Issuer
Sabater Juan A. (1821210) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:18 PM
Graf R. Mark (1494757) Reporting
Harmony Biosciences (1802665) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:18 PM
Harmony Biosciences (1802665) Issuer
Philip Ron M (2063957) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:19 PM
Harmony Biosciences (1802665) Issuer
Szyper Linda M (1739050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:31 PM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2026 8:24 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2026 7:16 AM
Harmony Biosciences (1802665) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/14/2026 7:15 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/09/2026 3:15 PM
Harmony Biosciences (1802665) Issuer
Zaeske Adam H. (2064712) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/06/2026 3:07 PM
Harmony Biosciences (1802665) Issuer
Ignelzi Troy A. (1579829) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/06/2026 3:14 PM
Harmony Biosciences (1802665) Issuer
Ignelzi Troy A. (1579829) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/06/2026 3:16 PM
Anastasiou Peter (1999888) Reporting
Harmony Biosciences (1802665) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 7:00 AM
Harmony Biosciences (1802665) Filer
Form DEF 14A
04/03/2026 7:05 AM
Harmony Biosciences (1802665) Filer
Form DEFA14A
04/03/2026 7:10 AM
Harmony Biosciences (1802665) Filer
Form ARS
04/02/2026 7:15 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2026 8:32 AM
Harmony Biosciences (1802665) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
02/24/2026 7:16 AM
Harmony Biosciences (1802665) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/24/2026 7:10 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/28/2026 7:19 PM
Harmony Biosciences (1802665) Issuer
Kapadia Sandip (1677141) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:43 PM
Dayno Jeffrey M. (1615993) Reporting
Harmony Biosciences (1802665) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:44 PM
Harmony Biosciences (1802665) Issuer
Zaeske Adam H. (2064712) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:45 PM
Budur Kumar (2009762) Reporting
Harmony Biosciences (1802665) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:48 PM
Harmony Biosciences (1802665) Issuer
Serafin Andrew (1821460) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:49 PM
Harmony Biosciences (1802665) Issuer
Kapadia Sandip (1677141) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:30 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/20/2026 7:39 PM
Harmony Biosciences (1802665) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
The cat is out the bag (Ad)

Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel

Watch Porter Stansberry's full investigation into the Final Displacement now
01/20/2026 7:39 PM
Harmony Biosciences (1802665) Issuer
Kapadia Sandip (1677141) Reporting
Kapadia Sandip (1677141) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 7:20 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/17/2025 4:25 PM
Dayno Jeffrey M. (1615993) Reporting
Harmony Biosciences (1802665) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 3:25 PM
Dayno Jeffrey M. (1615993) Reporting
Harmony Biosciences (1802665) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/09/2025 3:10 PM
Harmony Biosciences (1802665) Issuer
Kapadia Sandip (1677141) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2025 3:30 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2025 3:46 PM
Harmony Biosciences (1802665) Subject
Kapadia Sandip (1677141) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2025 4:03 PM
Harmony Biosciences (1802665) Subject
Valor IV Pharma Holdings, LLC (1821186) Filed by
Form SCHEDULE 13G/A
11/05/2025 10:35 AM
FMR LLC (315066) Filed by
Harmony Biosciences (1802665) Subject
Form SCHEDULE 13G/A
11/04/2025 7:42 AM
Harmony Biosciences (1802665) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/04/2025 7:05 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/23/2025 7:15 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/24/2025 7:39 AM
Harmony Biosciences (1802665) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/02/2025 4:45 PM
Gracias Antonio J. (1495158) Reporting
Harmony Biosciences (1802665) Issuer
Sabater Juan A. (1821210) Reporting
Valor Equity Associates IV L.P. (1822427) Reporting
Valor Equity Capital IV LLC (1821936) Reporting
VALOR EQUITY PARTNERS IV L.P. (1705506) Reporting
VALOR EQUITY PARTNERS IV-A L.P. (1705542) Reporting
VALOR EQUITY PARTNERS IV-B L.P. (1705512) Reporting
Valor IV Pharma Holdings, LLC (1821186) Reporting
Valor Management L.P. (1822428) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Harmony Biosciences SEC Filings - Frequently Asked Questions

Harmony Biosciences (HRMY) has submitted 285+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Harmony Biosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Harmony Biosciences's financial statements page.

The most recent filing was a Form 144 submitted on August 7, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:HRMY) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners